Application of pharmacogenomics to clinical problems in depression

Personalized Medicine
Svetlana Oestergaard, Claus Møldrup

Abstract

The goal of this article is to review the literature for evidence supporting an association between polymorphisms within drug target genes and clinical outcomes for treating depression, with a purpose to identify a research area having the most promising potential to be introduced into clinical settings, and thus, discussing the perspectives of genotyping in antidepressant therapy. A total of 67 articles were identified. Polymorphic sites within the serotonin transporter gene promoter, 5-HTTLPR, were the most studied polymorphisms. All except three articles were designed as cohort studies. The other three articles included two meta-analyses and one decision-analytic model. The main finding from these meta-analyses was that the l variant was associated with a better response to selective serotonin reuptake inhibitors. The main conclusion from the decision-analytic model study was that performing genetic testing before prescribing antidepressant treatment may lead to greater numbers of patients experiencing remission early in treatment. Clinical outcomes of genotyping this polymorphism were evaluated by improvement of depression score, odds ratio and absolute risk reduction.

References

Jun 1, 1996·Journal of Neurochemistry·A HeilsK P Lesch
Jul 1, 1997·Archives of General Psychiatry·R S DumanE J Nestler
Jul 22, 1998·The Journal of Clinical Psychiatry·S E Byrne, A J Rothschild
Feb 23, 2000·Neuroreport·D K KimB J Carroll
Oct 12, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·B G PollockD J Kupfer
Oct 13, 2001·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·A SerrettiE Smeraldi
Dec 14, 2001·AAPS PharmSci·L MancinelliW Sadée
Jan 31, 2002·Progress in Neuro-psychopharmacology & Biological Psychiatry·Keizo YoshidaKoichi Otani
Jun 12, 2002·The International Journal of Neuropsychopharmacology·Cristina CusinEnrico Smeraldi
Jun 20, 2003·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Peter ZillBrigitta Bondy
Jun 19, 2004·BMJ : British Medical Journal·David AtkinsUNKNOWN GRADE Working Group
Jul 27, 2004·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Alessandro SerrettiRaffaella Zanardi
Sep 1, 2004·The American Journal of Psychiatry·Keizo YoshidaCharles B Nemeroff
Sep 28, 2004·The International Journal of Neuropsychopharmacology·Sylvie LemondePaul R Albert
Oct 2, 2004·The International Journal of Neuropsychopharmacology·Alessandro SerrettiRaffaella Zanardi
Apr 7, 2005·International Clinical Psychopharmacology·Masaki KatoToshihiko Kinoshita
Jun 9, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Alessandro SerrettiEnrico Smeraldi
Jun 11, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Marcelo Páez-Pereda
Jun 14, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Klaus Peter Lesch, Lise Gutknecht
Jun 16, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Younger W-Y YuChih-Wei Yang
Aug 2, 2005·Nature Reviews. Drug Discovery·Julia KirchheinerJürgen Brockmöller
Oct 1, 2005·International Review of Psychiatry·A A BolonnaR W Kerwin

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy
genotyping

Software Mentioned

Cochrane

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.